Clinical Efficacy Study of PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Advanced Endometrial Cancer

Summary

Exploring the therapeutic effect of neoadjuvant chemotherapy combined with PD-1 inhibitor camrelizumab on advanced stage III-IV endometrial cancer

Conditions

• Endometrioid Endometrial Cancer

Interventions

DRUG

Camrelizumab

Camrelizumab is administered at 200mg, q3w，intravenous infusion

DRUG

Carboplatin

AUC=4-6，q3w，intravenous infusion

DRUG

Paclitaxel

175 mg/m2，q3w，intravenous infusion, administered over 30min.

PROCEDURE

Surgery

Transabdominal hysterectomy + bilateral adnexectomy + pelvic lymph node dissection + pelvic-abdominal tumor resection +/- para-abdominal aortic lymph node dissection

Sponsors & Collaborators

• Xiangya Hospital of Central South University

  collaborator OTHER

• Tongji Hospital

  collaborator OTHER

• Qilu Hospital of Shandong University

  collaborator OTHER

• Anhui Provincial Cancer Hospital

  collaborator OTHER

• Sichuan Cancer Hospital and Research Institute

  collaborator OTHER

• Henan Provincial People's Hospital

  collaborator OTHER

• Hunan Cancer Hospital

  collaborator OTHER

• Zhejiang Cancer Hospital

  collaborator OTHER

• First Affiliated Hospital of Wenzhou Medical University

  collaborator OTHER

• Ningbo No. 1 Hospital

  collaborator OTHER

• The First Affiliated Hospital of Zhengzhou University

  collaborator OTHER

• Women's Hospital School Of Medicine Zhejiang University

  lead OTHER

Principal Investigators

• Hui Wang, PHD · Women's Hospital School Of Medicine Zhejiang University

Study Design

Allocation

NA

Purpose

TREATMENT

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

18 Years

Max Age

75 Years

Sex

FEMALE

Healthy Volunteers

No

Timeline & Regulatory

Start

2025-09-01

Primary Completion

2026-12-01

Completion

2031-12-01

Countries

• China

Study Locations